The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events

Copyright © 2012 Elsevier Ltd. All rights reserved.

Bibliographic Details
Published in:Thrombosis research, Vol. 130, No. 3 (2012), p. 441-4
Main Author: Ahmad-Nejad, Parviz (Author)
Other Involved Persons: Dempfle, Carl-Erik ; Weiss, Christel ; Bugert, Peter ; Borggrefe, Martin ; Neumaier, Michael
Format: electronic Article
Language:English
ISSN:1879-2472
Item Description:Date Completed 31.01.2013
Date Revised 21.08.2012
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description:Online-Ressource
DOI:10.1016/j.thromres.2012.02.009
Subjects:
QR Code: Show QR Code
LEADER 04190nma a2200745 c 4500
001 NLM21616284X
003 DE-601
005 20181228092949.0
007 cr uuu---uuuuu
008 180205s2012 000 0 eng d
024 7 |a 10.1016/j.thromres.2012.02.009  |2 doi 
028 5 2 |a pubmed19n0720.xml 
035 |a (DE-599)NLM22421107 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Ahmad-Nejad, Parviz  |e verfasserin  |4 aut 
245 1 4 |a The G534E-polymorphism of the gene encoding the factor VII-activating protease is a risk factor for venous thrombosis and recurrent events  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 31.01.2013 
500 |a Date Revised 21.08.2012 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright © 2012 Elsevier Ltd. All rights reserved. 
520 |a INTRODUCTION: A single nucleotide polymorphism of the factor VII activating protease (FSAP), FSAP Marburg I (rs7080536) has been identified as a risk factor for venous thrombosis, but its clinical role has so far been controversial in part due to small cohort sizes. The aim of the present case-control study was to elucidate the impact of the FSAP Marburg I polymorphism (FSAP-MI) on the development of venous thromboembolic disease (VTE) with other known sequence variations, including Factor V Leiden (rs6025) and Factor II G20210A (rs1799963) 
520 |a MATERIALS AND METHODS: The study included 891 patients (312 male and 579 female) with a history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) and 1283 healthy blood donors with no history of venous thromboembolic disease 
520 |a RESULTS: We found that besides to the well-established aforementioned sequence variations of FV and Prothrombin, the FSAP Marburg I (FSAP-MI) polymorphism was significantly associated with the development of DVTs (1.65 (1.16-2.34) OR (95% CI)) and recurrent thromboembolic events (DVT and PE) (2.13 (1.35-3.36) OR (95% CI)). Comparing patients displaying one or more events FSAP-MI was still associated with the development of recurrent thromboembolic events (1.64 (1- 2.69) OR (95% CI)) 
520 |a CONCLUSIONS: We conclude that FSAP Marburg-I genotyping may be used to determine the risk for thromboembolic disorders in patients with suspected thrombophilia and known DVT or PE 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Female  |6 D005260 
653 2 |a Genetic Markers  |6 D005819  |a genetics  |6 Q000235 
653 2 |a Genetic Predisposition to Disease  |6 D020022  |a *epidemiology  |6 Q000453  |a *genetics  |6 Q000235 
653 2 |a Germany  |6 D005858  |a epidemiology  |6 Q000453 
653 2 |a Humans  |6 D006801 
653 2 |a Incidence  |6 D015994 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Polymorphism, Single Nucleotide  |6 D020641  |a *genetics  |6 Q000235 
653 2 |a Recurrence  |6 D012008 
653 2 |a Risk Factors  |6 D012307 
653 2 |a Serine Endopeptidases  |6 D012697  |a *genetics  |6 Q000235 
653 2 |a Venous Thrombosis  |6 D020246  |a enzymology  |6 Q000201  |a *epidemiology  |6 Q000453  |a *genetics  |6 Q000235 
655 7 |a Genetic Markers  |2 gnd 
655 7 |a HABP2 protein, human  |2 gnd 
655 7 |a EC 3.4.21.-  |2 gnd 
655 7 |a Serine Endopeptidases  |2 gnd 
655 7 |a EC 3.4.21.-  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 2 0 |a Genetic Markers 
689 2 1 |a HABP2 protein, human 
689 2 2 |A r  |a EC 3.4.21.- 
689 2 3 |a Serine Endopeptidases 
689 2 4 |A r  |a EC 3.4.21.- 
689 2 |5 DE-601 
700 1 |a Dempfle, Carl-Erik  |e verfasserin  |4 aut 
700 1 |a Weiss, Christel  |e verfasserin  |4 aut 
700 1 |a Bugert, Peter  |e verfasserin  |4 aut 
700 1 |a Borggrefe, Martin  |e verfasserin  |4 aut 
700 1 |a Neumaier, Michael  |e verfasserin  |4 aut 
773 0 8 |i in  |t Thrombosis research  |g Vol. 130, No. 3 (2012), p. 441-4  |q 130:3<441-4  |w (DE-601)NLM000010839  |x 1879-2472 
856 4 1 |u http://dx.doi.org/10.1016/j.thromres.2012.02.009  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 130  |j 2012  |e 3  |c 09  |h 441-4